Vtama in Psoriasis Patients Being Treated With Biologics. - Trial NCT06103695
Access comprehensive clinical trial information for NCT06103695 through Pure Global AI's free database. This Phase 4 trial is sponsored by Psoriasis Treatment Center of Central New Jersey and is currently Completed. The study focuses on Psoriasis. Target enrollment is 30 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Psoriasis Treatment Center of Central New Jersey
Timeline & Enrollment
Phase 4
Feb 27, 2023
Oct 18, 2023
Primary Outcome
Body surface area ≤1%
Summary
Open label study to assess 12 weeks of add-on VTAMA® (tapinarof) Cream, 1% QD in patients
 with ≥3% BSA who have received biologic therapy for at least 24 weeks.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06103695
Non-Device Trial